Apollo Care Recalls Semaglutide Vials Due to Particulate Matter
Apollo Care, LLC is recalling 500 vials of Semaglutide 10mg due to the presence of nylon and silk-type particulate matter.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classified this as an FDA Class II recall. Per the rubric, FDA Class II recalls are assigned a severity score of 4 (Severe), particularly when involving sterile injectable products where particulate matter poses a significant risk.
Plain-English summary
Apollo Care, LLC is recalling 500 vials of Semaglutide 10mg (5mg/mL), Glycine 10 mg (5mg/mL), 2 mL Sterile Multi-Dose Vials. The product is identified by NDC 71170-722-02, Lot AC-017274, and an expiration date of 12/12/2026. The recall was initiated because the vials contain particulate matter identified as nylon/polyamide and silk/proteinaceous-type material.
The affected product was distributed nationwide within the U.S. The agency has classified this recall as Class II. No specific illnesses or injuries are reported in the source text.
Consumers should stop using the recalled vials and contact their healthcare provider or pharmacist for instructions on how to return the product or obtain a replacement.
The recalled product
- Product
- SEMAGLUTIDE 10mg (5mg/mL), Glycine 10 mg (5mg/mL), 2 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-722-02
- Manufacturer
- Apollo Care, LLC
- Category
- Drug — Injectable Medication
- Affected units
- 500
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot: AC-017274
- Exp. 12/12/2026.
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Apollo Care, LLC
See all →- SevereApollo Care Recalls Semaglutide Vials Due to Particulate Matter
FDA (Drugs) · 2026-08-19
- SevereApollo Care Recalls Semaglutide Vials Due to Particulate Matter
FDA (Drugs) · 2026-08-19
- SevereApollo Care Recalls Semaglutide Vials Due to Particulate Matter
FDA (Drugs) · 2026-08-19
- SevereApollo Care Recalls Semaglutide Vials Due to Particulate Matter
FDA (Drugs) · 2026-08-19
- SevereApollo Care Recalls Semaglutide Vials Due to Particulate Matter
FDA (Drugs) · 2026-08-19
Same hazard · particulate matter
See all →- ModerateIMAAVY Injection Recalled for Presence of Particulate Matter
FDA (Drugs) · 2026-10-14
- HighICU Medical Recalls IV Sets with Potential Drip Chamber Discoloration
FDA (Devices) · 2026-09-23
- HighICU Medical Recalls IV Sets with Potential Drip Chamber Discoloration
FDA (Devices) · 2026-09-23
- HighICU Medical Recalls Plum Administration Sets Due to Drip Chamber Discoloration
FDA (Devices) · 2026-09-23
- HighICU Medical Recalls IV Sets with Potential Drip Chamber Discoloration
FDA (Devices) · 2026-09-23
Similar recalls
- SevereApollo Care Recalls Semaglutide Vials Due to Particulate Matter
FDA (Drugs) · 2026-08-19
- HighSemaglutide injection multi-dose vials recalled over lack of sterility assurance
FDA (Drugs) · 2026-03-11
- HighCompounded Semaglutide Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2024-09-11
- HighSemaglutide 10 mg vials recalled for lack of sterility assurance
FDA (Drugs) · 2025-11-05
- HighSemaglutide injection vials recalled over lack of sterility assurance
FDA (Drugs) · 2026-03-11
- HighSemaglutide Injection Recalled Due to Sterility Assurance Deficiency
FDA (Drugs) · 2022-11-09